Differential Effects of Carbachol and Oxotremorine on Muscarinic Receptors, Cyclic Amp Formation, and Phosphoinositide Turnover in Chick Heart Cells

  • J. H. Brown
  • S. B. Masters
Part of the Advances in Behavioral Biology book series (ABBI, volume 30)


A central theme in current studies of muscarinic receptors is the definition of muscarinic receptor subtypes. Early evidence for the existence of such receptor subtypes came from studies of physiological responses mediated through muscarinic receptors in various tissues (1, 7). More recently, investigators have used radioligand binding studies to look for muscarinic receptor subtypes. Attempts to distinguish subtypes with classical antagonists have not been fruitful since these agents generally recognize a uniform population of binding sites (9). Several non-classical antagonists such as gallamine (8) and pirenzepine (10) do appear to show selectivety in radioligand binding assays, but gallamine probably acts at a site that is different from the primary antagonist binding site (8) and the selectivity of pirenzepine has been disputed (11).


Muscarinic Receptor Cholinergic Agonist Radioligand Binding Assay Muscarinic Receptor Subtype Receptor Binding Property 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barlow, R.B., Berry, K.J., Glanton, P.A.M., Nikolaou, N.M. and Soh, K.S. (1976): Br. J. Pharmacol. 58: 613–620.Google Scholar
  2. 2.
    Berridge, M.J., Downes, C.P. and Hanley, M.R. (1982): Biochem. J. 206: 587–595.Google Scholar
  3. 3.
    Birdsall, N.J.M., Burgen, A.S.V. and Hulme, E.C. (1978): Mol. Pharmacol. 14: 723–736.Google Scholar
  4. 4.
    Brown, J.H. and Brown, S.L. (1984): J. Biol. Chem. 259: 3777–3781.Google Scholar
  5. 5.
    Brown, J.H. and Brown, S.L. (1984): Fed. Proc. 43: 2613–2617.Google Scholar
  6. 6.
    Brown,S.L. and Brown,J.H. (1983): Mol. Pharmacol. 24: 351–356.Google Scholar
  7. 7.
    Burgen, A.S.V. and Spero, L. (1968): Br. J. Pharmacol. 34: 99–115.Google Scholar
  8. 8.
    Dunlap, J. and Brown, J.H. (1983): Mol. Pharmacol. 24: 15–22.Google Scholar
  9. 9.
    Ehlert, F.J., Roeske, W.R. and Yamamura, H.I. (1981): Fed. Proc. 40: 153–159.Google Scholar
  10. 10.
    Hammer, R., Berrie, C.P., Birdsall, N.J.M., Burgen, A.S.V. and Hulme, E.C. (1980): Nature 283: 90–92.CrossRefGoogle Scholar
  11. 11.
    Laduron, P.M., Leysen, J.E. and Gorissen, H. (1981): Arch. Int. Pharmacodyn. 249: 319–321.Google Scholar
  12. 12.
    Munson, P.J. andRodbard, D. (1980): Anal. Biochem. 107: 220–239.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • J. H. Brown
    • 1
  • S. B. Masters
    • 1
  1. 1.Division of PharmacologyUniversity of California, San DiegoLa JollaUSA

Personalised recommendations